Bearish
Candel Therapeutics 1Q 2026: Net income $(8.9)M, EPS $(0.14) — 10-Q Summary
Candel Therapeutics reported a net loss of $(8.9)M and diluted EPS of $(0.14) for Q1 2026, a significant downturn from the previous year's positive fi...